LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Lomholt, Frederikke K.; Laulund, Anne S.; Bjarnason, Nina H.; Jørgensen, Henrik L.; Godtfredsen, Nina Skavlan (2014)
Publisher: Co-Action Publishing
Journal: European Clinical Respiratory Journal
Languages: English
Types: Article
Subjects: Original Research Article, mortality, blood tests, meta-analysis, COPD

Classified by OpenAIRE into

mesheuropmc: education
Objective: The purpose of this study was to examine whether routine blood tests can be useful in predicting mortality in COPD patients.Methods: Eligible studies were found through a search conducted in the PubMed and Embase databases, the Cochrane Library, and the Web of Knowledge. Twelve studies were included for the meta-analysis of five biochemical markers. Pooled odds ratios (ORs), matching 95% confidence intervals (CIs), and p-values for each of the biochemical markers were calculated using the random effect model.Results: The following four examined biochemical markers were shown to be associated with mortality in patients suffering from COPD: anemia (OR=2.62, 95% CI: 1.60; 4.29, p=0.01), hypoalbuminemia (OR=2.90, 95% CI: 1.56; 5.40, p=0.0008), elevated NT-proBNP (OR=7.54, 95% CI: 4.04; 14.10, p<0.00001), and elevated cardiac troponin T (OR=3.10, 95% CI: 1.11; 8.25, p=0.03). hs-CRP was not found to be associated with increased mortality.Conclusion: In this study, we found that anemia, hypoalbuminemia, elevated NT-proBNP, and elevated cardiac troponin T were associated with increased mortality in patients suffering from COPD.Keywords: COPD; mortality; blood tests; meta-analysis(Published: 5 June 2014)Citation: European Clinical Respiratory Journal 2014, 1: 24110 - http://dx.doi.org/10.3402/ecrj.v1.24110
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Vestbo J, Hurd SS, Agust´ı AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187: 347 65.
    • 2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370: 765 73.
    • 3. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006; 28: 1245 57.
    • 4. WHO. Chronic obstructive pulmonary disease (COPD) [updated 2013 October]. http://www.who.int/mediacentre/factsheets/ fs315/en/index.html [cited 2013 October 17].
    • 5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442.
    • 6. Sta˚hl E, Lindberg A, Jansson SA, Ro¨ nmark E, Svensson K, Andersson F. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005; 3: 56.
    • 7. Rutten-van Mo¨ lken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest. 2006; 130: 1117 28.
    • 8. Barnes N, Calverley PM, Kaplan A, Rabe KF. Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD survey. BMC Pulm Med. 2013; 13: 54.
    • 9. Vestbo J1, Agusti A, Wouters EF, Bakke P, Calverley PM, Celli B. Should we view COPD differently after ECLIPSE? A Clinical Perspective from the Study Team. Am J Respir Crit Care Med. 2014; 189: 1022 30.
    • 10. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000; 118: 1278 85.
    • 11. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006; 27: 188 207.
    • 12. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest. 2003; 123: 784 91.
    • 13. Martinez-Rivera C, Portillo K, Mun˜ oz-Ferrer A, Mart´ınezOrtiz ML, Molins E, Serra P, et al. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD. 2012; 9: 243 50.
    • 14. Haja Mydin H, Murphy S, Clague H, Sridharan K, Taylor IK. Anemia and performance status as prognostic markers in acute hypercapnic respiratory failure due to chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013; 8: 151 7.
    • 15. Kollert F, Tippelt A, Mu¨ ller C, Jo¨ rres RA, Porzelius C, Pfeifer M, et al. Hemoglobin levels above anemia thresholds are maximally predictive for long-term survival in COPD with chronic respiratory failure. Respir Care. 2013; 58: 1204 12.
    • 16. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007; 29: 923 9.
    • 17. Rasmussen L, Christensen S, Lenler-Petersen P, Johnsen SP. Anemia and 90-day mortality in COPD patients requiring invasive mechanical ventilation. Clin Epidemiol. 2010; 3: 1 5.
    • 18. Boutou AK, Karrar S, Hopkinson NS, Polkey MI. Anemia and survival in chronic obstructive pulmonary disease: a dichotomous rather than a continuous predictor. Respiration. 2013; 85: 126 31.
    • 19. Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011; 66: 764 8.
    • 20. Høiseth AD, Omland T, Hagve TA, Brekke PH, Søyseth V. NT-proBNP independently predicts long term mortality after acute exacerbation of COPD a prospective cohort study. Respir Res. 2012; 13: 97.
    • 21. Marcun R, Sustic A, Brguljan PM, Kadivec S, Farkas J, Kosnik M, et al. Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. Int J Cardiol. 2012; 161: 156 9.
    • 22. Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005; 26: 234 41.
    • 23. Poggiali E, Migone De Amicis M, Motta I. Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases. Eur J Intern Med. 2014; 25: 12 7. doi: 10.1016/ j.ejim.2013.07.011.
    • 24. Bland M, Altman DG. Statistical notes: the odds ratio. BMJ. 2000; 320: 1468.
    • 25. Walker E, Hernandez AV, Kattan MW. Meta-analysis: its strengths and limitations. Clev Clin J Med. 2008; 75: 431 9.
    • 26. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009; 62: e1 34.
    • 27. Liu SF, Wang CC, Chin CH, Chen YC, Lin MC. High value of combined serum C-reactive protein and BODE score for mortality prediction in patients with stable COPD. Arch Bronconeumol. 2011; 47: 427 32.
    • 28. de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Co´ rdoba-Lanu´ s E, Muros de Fuentes M, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest. 2008; 133: 1336 43.
    • 29. Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J. 2011; 161: 822 31.
    • 30. Lawler PR, Filion KB, Eisenberg MJ. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents. J Card Fail. 2010; 16: 649 58.
    • 31. Portillo K, Martinez-Rivera C, Ruiz-Manzano J. Anaemia in chronic obstructive pulmonary disease. Does it really matter? Int J Clin Pract. 2013; 67: 558 65.
    • 32. Scho¨ nhofer B, Wenzel M, Geibel M, Ko¨ hler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med. 1998; 26: 1824 8.
    • 33. Scho¨ nhofer B, B o¨hrer H, Ko¨ hler D. Blood transfusion facilitating difficult weaning from the ventilator. Anaesthesia. 1998; 53: 181 4.
    • 34. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10: 824 39.
    • 35. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G, Arakaki D, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012; 39: 51 8.
    • 36. McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003; 10: 198 204.
    • 37. Brekke PH, Omland T, Holmedal SH, Smith P, Søyseth V. Determinants of cardiac troponin T elevation in COPD exacerbation a cross-sectional study. BMC Pulm Med. 2009; 9: 35.
    • 38. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59: 574 80.
  • No similar publications.

Share - Bookmark

Cite this article